These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19628708)

  • 1. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo.
    Romay-Penabad Z; Montiel-Manzano MG; Shilagard T; Papalardo E; Vargas G; Deora AB; Wang M; Jacovina AT; Garcia-Latorre E; Reyes-Maldonado E; Hajjar KA; Pierangeli SS
    Blood; 2009 Oct; 114(14):3074-83. PubMed ID: 19628708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin.
    Pierangeli SS; Espinola RG; Liu X; Harris EN
    Circ Res; 2001 Feb; 88(2):245-50. PubMed ID: 11157679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR4 is involved in the pathogenic effects observed in a murine model of antiphospholipid syndrome.
    Xie H; Kong X; Zhou H; Xie Y; Sheng L; Wang T; Xia L; Yan J
    Clin Immunol; 2015 Oct; 160(2):198-210. PubMed ID: 26065621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.
    Pierangeli SS; Colden-Stanfield M; Liu X; Barker JH; Anderson GL; Harris EN
    Circulation; 1999 Apr; 99(15):1997-2002. PubMed ID: 10209004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro effects of antiphospholipid syndrome-IgG fractions and human monoclonal antiphospholipid IgG antibody on human umbilical vein endothelial cells and monocytes.
    Clemens N; Frauenknecht K; Katzav A; Sommer C; von Landenberg P
    Ann N Y Acad Sci; 2009 Sep; 1173():805-13. PubMed ID: 19758232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E-Selectin mediates pathogenic effects of antiphospholipid antibodies.
    Espinola RG; Liu X; Colden-Stanfield M; Hall J; Harris EN; Pierangeli SS
    J Thromb Haemost; 2003 Apr; 1(4):843-8. PubMed ID: 12871424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies.
    Carrera-Marín A; Romay-Penabad Z; Papalardo E; Reyes-Maldonado E; García-Latorre E; Vargas G; Shilagard T; Pierangeli S
    Lupus; 2012 Dec; 21(14):1497-505. PubMed ID: 22933620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells.
    Pierangeli SS; Harris EN
    Lupus; 2003; 12(7):539-45. PubMed ID: 12892395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annexin A2: biology and relevance to the antiphospholipid syndrome.
    Cockrell E; Espinola RG; McCrae KR
    Lupus; 2008 Oct; 17(10):943-51. PubMed ID: 18827060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4.
    Laplante P; Fuentes R; Salem D; Subang R; Gillis MA; Hachem A; Farhat N; Qureshi ST; Fletcher CA; Roubey RA; Merhi Y; Thorin É; Levine JS; Mackman N; Rauch J
    Lupus; 2016 Feb; 25(2):162-76. PubMed ID: 26391610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiphospholipid antibody-induced cellular responses depend on epitope specificity : implications for treatment of antiphospholipid syndrome.
    Müller-Calleja N; Hollerbach A; Häuser F; Canisius A; Orning C; Lackner KJ
    J Thromb Haemost; 2017 Dec; 15(12):2367-2376. PubMed ID: 29024318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype.
    Meroni PL; Raschi E; Testoni C; Tincani A; Balestrieri G; Molteni R; Khamashta MA; Tremoli E; Camera M
    Arthritis Rheum; 2001 Dec; 44(12):2870-8. PubMed ID: 11762948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice.
    Manukyan D; Müller-Calleja N; Jäckel S; Luchmann K; Mönnikes R; Kiouptsi K; Reinhardt C; Jurk K; Walter U; Lackner KJ
    J Thromb Haemost; 2016 May; 14(5):1011-20. PubMed ID: 26786324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome.
    Romay-Penabad Z; Aguilar-Valenzuela R; Urbanus RT; Derksen RH; Pennings MT; Papalardo E; Shilagard T; Vargas G; Hwang Y; de Groot PG; Pierangeli SS
    Blood; 2011 Jan; 117(4):1408-14. PubMed ID: 21119114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation.
    Di Simone N; Marana R; Castellani R; Di Nicuolo F; D'Alessio MC; Raschi E; Borghi MO; Chen PP; Sanguinetti M; Caruso A; Meroni PL
    Arthritis Rheum; 2010 May; 62(5):1504-12. PubMed ID: 20131286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.
    Ferrara DE; Liu X; Espinola RG; Meroni PL; Abukhalaf I; Harris EN; Pierangeli SS
    Arthritis Rheum; 2003 Nov; 48(11):3272-9. PubMed ID: 14613293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis.
    Pericleous C; Ruiz-Limón P; Romay-Penabad Z; Marín AC; Garza-Garcia A; Murfitt L; Driscoll PC; Latchman DS; Isenberg DA; Giles I; Ioannou Y; Rahman A; Pierangeli SS
    Rheumatology (Oxford); 2015 Apr; 54(4):722-7. PubMed ID: 25273993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells.
    Vega-Ostertag M; Liu X; Kwan-Ki H; Chen P; Pierangeli S
    Br J Haematol; 2006 Oct; 135(2):214-9. PubMed ID: 16965389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.